You are here
Treatment options for first-line therapies in advanced ccRCC
Commentary from Professor Susanne Osanto
10th April 2014
Dr. Motzer et al. reported a combined analysis of two open-label non-inferiority trials which compared pazopanib with sunitinib in a 1:1 ratio with respect to progression-free survival in renal-cell carcinoma. Thus, 1,110 patients with clear-cell, metastatic renal-cell carcinoma received a continuous dose of pazopanib or sunitinib in 6-week cycles. Progression-free survival (PFS) was the primary endpoint.
The authors concluded that pazopanib was non-inferior to sunitinib with respect to progression-free survival (hazard ratio for progression of disease or death from any cause, 1.05; 95% confidence interval [CI], 0.90 to 1.22) whereas overall survival (OS) was similar (hazard ratio for death with pazopanib, 0.91; 95% CI, 0.76 to 1.08). Despite critical comments on the statistical analysis of the trial, the data are supportive of pazopanib as an alternative for first-line treatment in metastatic clear cell kidney cancer next to sunitinib.
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK.
N Engl J Med. 2013 Aug 22;369(8):722-31.